Jared Kaltwasser

A case report suggests vigilance is required even when cancers like acute lymphoblastic leukemia appear to go into remission without explanation.

Experts argue for new mechanisms to fund research in oft-ignored rare diseases.

Better reporting is needed to create better guidelines for tracking infection risk in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, investigators concluded.

The analysis represents an effort to use bioinformatics to find potential new therapeutic targets for myasthenia gravis (MG).

Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and relapse-free survival.

Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs).

Investigators wanted to know how well the NFlymSI-18 assessment was able to assess patient-reported outcomes in people with indolent B-cell non-Hodgkin lymphoma (NHL).

A new study suggests inhibiting ActivinA might improve the efficacy of chemotherapy in patients with B-cell acute lymphoblastic leukemia (B-ALL).

A new report shows wide variability in terms of which patients with chronic thromboembolic pulmonary hypertension (CTEPH) are deemed eligible for pulmonary endarterectomy and balloon pulmonary angioplasty.

The findings show most patients with low-risk myelodysplastic syndrome (MDS) will die before progression.

A new report offers safety and efficacy data on a population with generalized myasthenia gravis (gMG) not represented in the drug’s pivotal phase 3 trial.

The therapy led to increased frataxin levels and decreased left ventricular mass in patients with Friedreich ataxia (FA) cardiomyopathy, the authors said.

Patients with myelodysplastic syndrome (MDS) in the treatment arm were more likely to achieve transfusion independence, but the difference vs placebo was not statistically significant.

It is rare for patients with chronic lymphocytic leukemia (CLL) to present with ocular involvement, but a mutational test could help clinicians identify patients more quickly.

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are rare in Japan, but a new report affirms the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) (VenR) in this population.

Quality of life was also a top concern among patients when asked about their priorities if they experienced relapse or were refractory to therapy.

Early tests show stem cells can be used to spark expression of a miniature version of the dystrophin protein.

Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.

Different types of assays led to different results in measures of factor IX variant FIX-R338L, the authors found.

A new study also found a lack of correlation between physical activity levels and bleeding episodes among people with hemophilia A.

People receiving hypomethylating agent (HMA) therapy spent 33 more days at home than people receiving anthracycline-based therapy in the first year after diagnosis.

A new prevalence study shows more people are living beyond age 65 with type 1 diabetes (T1D).

A Chinese study shows hypertension management led by nonphysicians can be safe and effective.

The most common treatment-related adverse events were injection site reactions, the study found.

There currently are no guidelines on how to treat this patient group, despite a high risk of mortality.

Men are less likely than women to desire community when exercising, the authors found.

The authors said their analysis should help clinicians better monitor patients for potential adverse events.

The coalition said, however, that patient-reported outcomes (PROs) in the myelodysplastic syndrome (MDS) space will be most meaningful if they are collected rigorously and if the data are transparent.

The new data shed light on long-term outcomes for patients receiving duvelisib, although the investigators said the treatment landscape has also shifted significantly since the original trial.

The report found a selective serotonin reuptake inhibitor (SSRI) did not offset the effects of myasthenia gravis (MG) medication.